alexa Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine.


Journal of Kidney

Author(s): Sastry J, Kellie SJ

Abstract Share this page

Abstract Cisplatin in higher doses have been used routinely in the treatment of childhood tumours including neuroblastoma and germ cell tumors. Amifostine, a broad-spectrum cytoprotector of normal tissues, has been approved by U.S. Food and Drug Administration for use in patients receiving cisplatin. Such administration of amifostine has been reported to reduce cisplatin-related toxicities in some studies, but not all. The authors report a case of severe toxicity with cisplatin in a girl with epithelial cell carcinoma of the ovary despite the use of amifostine. This article was published in Pediatr Hematol Oncol and referenced in Journal of Kidney

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

  • 2nd Annual Kidney Congress
    Aug 28-30, 2017, Philadelphia, USA
  • 16th European Nephrology Conference
    Oct 02-04, 2017, Barcelona, Spain
  • 16th International Conference on Nephrology
    Nov 02-03, 2017, Atlanta, USA

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version